tradingkey.logo

Kamada Ltd

KMDA
View Detailed Chart
6.660USD
+0.040+0.60%
Close 11/07, 16:00ETQuotes delayed by 15 min
382.98MMarket Cap
20.15P/E TTM

Kamada Ltd

6.660
+0.040+0.60%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.60%

5 Days

-3.76%

1 Month

-2.63%

6 Months

-4.72%

Year to Date

+9.36%

1 Year

+11.00%

View Detailed Chart

TradingKey Stock Score of Kamada Ltd

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Kamada Ltd's Score

Industry at a Glance

Industry Ranking
59 / 159
Overall Ranking
166 / 4614
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 3 analysts
Buy
Current Rating
16.000
Target Price
+140.24%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Kamada Ltd Highlights

StrengthsRisks
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 24.44% year-on-year.
Fairly Valued
The company’s latest PE is 20.09, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 26.72M shares, decreasing 9.81% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 253.27K shares of this stock.

Kamada Ltd News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Kamada Ltd Info

Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Ticker SymbolKMDA
CompanyKamada Ltd
CEOMr. Amir London
Websitehttps://www.kamada.com/
KeyAI